In Hodgkin’s Disease CD30, which is highly expressed on malignant RS cells is a target56 and in preclinical studies CD30 CAR+ EBV-CTLs retain their ability to kill EBV-positive lymphoma cells and have the ability to recognize and kill CD30+ HD tumor cells in vitro and in vivo in a severe combined immunodeficiency murine model. This evidence concerns the gene TNFRSF8 and severe combined immunodeficiency.